565 related articles for article (PubMed ID: 21679733)
1. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
2. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
3. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
5. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
6. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Elamanchili P; Diwan M; Cao M; Samuel J
Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402
[TBL] [Abstract][Full Text] [Related]
7. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles.
Ghotbi Z; Haddadi A; Hamdy S; Hung RW; Samuel J; Lavasanifar A
J Drug Target; 2011 May; 19(4):281-92. PubMed ID: 20590403
[TBL] [Abstract][Full Text] [Related]
8. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
9. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
10. Targeting nanoparticles to dendritic cells for immunotherapy.
Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
12. Immune system targeting by biodegradable nanoparticles for cancer vaccines.
Silva JM; Videira M; Gaspar R; Préat V; Florindo HF
J Control Release; 2013 Jun; 168(2):179-99. PubMed ID: 23524187
[TBL] [Abstract][Full Text] [Related]
13. Harnessing Dendritic Cells for Poly (D,L-lactide-
Koerner J; Horvath D; Groettrup M
Front Immunol; 2019; 10():707. PubMed ID: 31024545
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines.
Acharya AP; Clare-Salzler MJ; Keselowsky BG
Biomaterials; 2009 Sep; 30(25):4168-77. PubMed ID: 19477505
[TBL] [Abstract][Full Text] [Related]
16. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.
Cruz LJ; Tacken PJ; Fokkink R; Joosten B; Stuart MC; Albericio F; Torensma R; Figdor CG
J Control Release; 2010 Jun; 144(2):118-26. PubMed ID: 20156497
[TBL] [Abstract][Full Text] [Related]
17. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of biodegradable nanoparticles as antigen delivery system.
Petrizzo A; Conte C; Tagliamonte M; Napolitano M; Bifulco K; Carriero V; De Stradis A; Tornesello ML; Buonaguro FM; Quaglia F; Buonaguro L
J Exp Clin Cancer Res; 2015 Oct; 34():114. PubMed ID: 26444005
[TBL] [Abstract][Full Text] [Related]
19. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
20. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.
Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP
Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]